File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Translational Contrast Agents for Use in Fluorescence Image-Guided Tumor Surgery

TitleTranslational Contrast Agents for Use in Fluorescence Image-Guided Tumor Surgery
Authors
KeywordsImage-guided surgery
Nanomaterial
Peptide
Self-assembly
Tumor
Issue Date13-Jul-2025
PublisherElsevier
Citation
Biomaterials, 2025, v. 325 How to Cite?
Abstract

Currently, surgical intervention remains the foundation in curing most solid tumors. Over the past few decades, even with rapid intraoperative tissue pathology assessment, the overall rate of positive surgical margins for tumors stagnated between 15 % and 60 %. The increased local recurrence rates and poor prognoses associated with various cancers, such as head and neck, brain, breast, lung, prostate, and gastrointestinal cancers, are linked to positive margins. Recently, driven by the concept of precise surgery, significant advancements have been reported in the intraoperative use of fluorescent contrast agents in the field of surgery. Molecular imaging via intraoperative fluorescence plays a guiding role in surgery, providing surgeons with visible fluorescent images. In clinical applications, fluorescent contrast agents can clearly delineate tumor boundaries, offering high recognition capacities and real-time guidance during surgery. Additionally, they can localize lymph node metastases, detect small metastatic lesions, and identify critical anatomical structures during surgery, thus reducing the risk of collateral damage. An ideal surgical guidance technology should lack radiation and display a high sensitivity and good resolution and an adjustable field of view, with rapid imaging. Enhancing the tissue penetration of fluorescence and targeting capacities of molecular probes are critical in providing more comprehensive tumor-related data. Additionally, screening and identifying other tumor biomarkers and more of their corresponding targeted molecular data are essential in enhancing the specificity of molecular imaging. Finally, the investigation and use of a wider range of near-infrared fluorescent dyes with improved biocompatibilities and imaging are critical in designing synthetic probes for application in intraoperative navigation. The development of novel, efficient, safe fluorescent contrast agents is a critical direction in current pharmaceutical research and development.


Persistent Identifierhttp://hdl.handle.net/10722/358435
ISSN
2023 Impact Factor: 12.8
2023 SCImago Journal Rankings: 3.016

 

DC FieldValueLanguage
dc.contributor.authorHou, Da-Yong-
dc.contributor.authorLi, Xiang-Peng-
dc.contributor.authorWang, Yue-Ze-
dc.contributor.authorZhang, Peng-
dc.contributor.authorWu, Jiong-Cheng-
dc.contributor.authorYou, Hui-Hui-
dc.contributor.authorLv, Mei-Yu-
dc.contributor.authorZhou, Shi-An-
dc.contributor.authorLiu, Xiao-
dc.contributor.authorZhang, Gao-
dc.contributor.authorAn, Hong-Wei-
dc.contributor.authorWang, Hao-
dc.contributor.authorXu, Wanhai -
dc.date.accessioned2025-08-07T00:32:19Z-
dc.date.available2025-08-07T00:32:19Z-
dc.date.issued2025-07-13-
dc.identifier.citationBiomaterials, 2025, v. 325-
dc.identifier.issn0142-9612-
dc.identifier.urihttp://hdl.handle.net/10722/358435-
dc.description.abstract<p>Currently, surgical intervention remains the foundation in curing most solid tumors. Over the past few decades, even with rapid intraoperative tissue pathology assessment, the overall rate of positive surgical margins for tumors stagnated between 15 % and 60 %. The increased local recurrence rates and poor prognoses associated with various cancers, such as head and neck, brain, breast, lung, prostate, and gastrointestinal cancers, are linked to positive margins. Recently, driven by the concept of precise surgery, significant advancements have been reported in the intraoperative use of fluorescent contrast agents in the field of surgery. Molecular imaging via intraoperative fluorescence plays a guiding role in surgery, providing surgeons with visible fluorescent images. In clinical applications, fluorescent contrast agents can clearly delineate tumor boundaries, offering high recognition capacities and real-time guidance during surgery. Additionally, they can localize lymph node metastases, detect small metastatic lesions, and identify critical anatomical structures during surgery, thus reducing the risk of collateral damage. An ideal surgical guidance technology should lack radiation and display a high sensitivity and good resolution and an adjustable field of view, with rapid imaging. Enhancing the tissue penetration of fluorescence and targeting capacities of molecular probes are critical in providing more comprehensive tumor-related data. Additionally, screening and identifying other tumor biomarkers and more of their corresponding targeted molecular data are essential in enhancing the specificity of molecular imaging. Finally, the investigation and use of a wider range of near-infrared fluorescent dyes with improved biocompatibilities and imaging are critical in designing synthetic probes for application in intraoperative navigation. The development of novel, efficient, safe fluorescent contrast agents is a critical direction in current pharmaceutical research and development.<br></p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofBiomaterials-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectImage-guided surgery-
dc.subjectNanomaterial-
dc.subjectPeptide-
dc.subjectSelf-assembly-
dc.subjectTumor-
dc.titleTranslational Contrast Agents for Use in Fluorescence Image-Guided Tumor Surgery-
dc.typeArticle-
dc.identifier.doi10.1016/j.biomaterials.2025.123549-
dc.identifier.scopuseid_2-s2.0-105010565837-
dc.identifier.volume325-
dc.identifier.eissn1878-5905-
dc.identifier.issnl0142-9612-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats